Piper Jaffray reiterated a Neutral rating and $5.00 price target on Sangamo BioSciences (NASDAQ: SGMO) following the company's 4Q earnings ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

Sangamo Biosciences (SGMO) Tops Q4 EPS by 11cFebruary 28, 2017 7:02 AM Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial ResultsFebruary 28, 2017 7:00 AM Sangamo Biosciences (SGMO) CFO to Retire; Successor NamedFebruary 27, 2017 4:53 PM Sangamo Therapeutics Announces Chief Financial Officer SuccessionFebruary 27, 2017 4:31 PM Sangamo (SGMO) Announces Rare Pediatric Disease Designation From FDA For SB-318February 27, 2017 8:10 AM Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318 In Vivo Genome Editing Therapeutic For MPS IFebruary 27, 2017 8:00 AM